Evidence map›Paper›PMID 40405591›Full record

ArticleFEBS open bio2025

Identifying prognostic targets in metastatic prostate cancer beyond AR.

Emily Feng, Eric Feng, Tracy Berg, Isabella S Nguyen, Lilac G Nguyen, William Chen, Meng Zhang, David Quigley, Marina Sharifi, Haolong Li and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS open bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Emily FengDepartment of Radiation Oncology, University of California San Francisco, CA, USA.
Eric FengDepartment of Radiation Oncology, University of California San Francisco, CA, USA.ORCID https://orcid.org/0000-0002-0906-0558
Tracy BergDepartment of Human Oncology, University of Wisconsin, Madison, WI, USA.
Isabella S NguyenDepartment of Radiation Oncology, University of California San Francisco, CA, USA.
Lilac G NguyenDepartment of Radiation Oncology, University of California San Francisco, CA, USA.
William ChenDepartment of Radiation Oncology, University of California San Francisco, CA, USA.
Meng ZhangDepartment of Radiation Oncology, University of California San Francisco, CA, USA.
David QuigleyDepartment of Radiation Oncology, University of California San Francisco, CA, USA.
Marina SharifiDepartment of Medicine, University of Wisconsin, Madison, WI, USA.
Haolong LiHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Ilsa ColemanHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Peter S NelsonHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID https://orcid.org/0000-0002-5451-5726
Martin SjöströmDepartment of Radiation Oncology, University of California San Francisco, CA, USA.ORCID https://orcid.org/0000-0002-2629-9966
Shuang G ZhaoDepartment of Human Oncology, University of Wisconsin, Madison, WI, USA.ORCID https://orcid.org/0000-0002-9166-6507

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · FRED HUTCHINSON CANCER RESEARCH CENTER · 2002 to 2025
$12.1M
Research Specialist in Cancer Genomics to Integrate Basic Research and Clinical DataR50CA274336 · FRED HUTCHINSON CANCER CENTER · 2025 to 2025
$113k
DoD PC190039DoD PC200334DoD PC210122DoD PC230420Hjelms Stiftelse för Medicinsk ForskningInstitute for Prostate Cancer ResearchNCI NIH HHS DP2 CA271832NCI NIH HHS P50 CA097186NCI NIH HHS R50 CA274336NIH HHS 1DP2CA271832-01NIH HHS P50CA097186NIH HHS R50CA274336Prostate Cancer FoundationSwedish Cancer Society (Cancerfonden)Swedish Prostate Cancer Foundation (Prostatacancerförbundet)
6 · The paper itself

Abstract

Genome-wide screens using CRISPR/RNAi can identify new therapeutic vulnerabilities in prostate cancer. In this study, we combine DepMap functional screen data with a large gene expression database (N = 1012) and clinical outcomes to identify potentially druggable targets. Eight genes (CYC, CYP51A1, DHFR, EBP, KIF15, PPM1D, SQLE, and UMPS) demonstrated strong dependency in cell lines and were also associated with worse prognosis clinically, representing potential therapeutic targets in metastatic prostate cancer. Four of these (DHFR, EBP, KIF15, and PPM1D) demonstrated higher expression in neuroendocrine prostate cancer. Furthermore, all but one (KIF15) were not significantly decreased from pretreatment to posttreatment, suggesting that they may remain targetable postabiraterone therapy. All eight genes showed evidence of protein expression in prostate cancers or cell lines. These potentially druggable targets associated with prostate cancer cell line dependency and worse clinical outcomes have also demonstrated literature support as potential targets, supporting further research into their potential clinical relevance as therapeutic targets in prostate cancer.

Indexed as

Prostatic NeoplasmsReceptors, AndrogenBiomarkers, TumorCell Line, TumorGene Expression Regulation, NeoplasticHumansMaleNeoplasm MetastasisPrognosisAR protein, humanBiomarkers, TumorReceptors, AndrogenclinicogenomicDepMapprostate cancer

Identifiers

PMID40405591
PMCPMC12582979

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.